Aβ Species Removal After Aβ42Immunization
Open Access
- 1 November 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology and Experimental Neurology
- Vol. 65 (11) , 1040-1048
- https://doi.org/10.1097/01.jnen.0000240466.10758.ce
Abstract
Neuropathologic examination of 3 patients with Alzheimer disease in the Elan Pharmaceuticals trial using antibodies specific for different Aβ speciesKeywords
This publication has 31 references indexed in Scilit:
- Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodiesAnnals of Neurology, 2005
- Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the ProteasomeNeuron, 2004
- An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-β DerivativesJournal of Neuroscience, 2004
- Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid DepositionJournal of Neuroscience, 2004
- Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP miceNeurobiology of Disease, 2003
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and TanglesNeuron, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s DiseaseNeurobiology of Aging, 1997
- Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brainNeuroscience Letters, 1996
- Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaquesNeuron, 1995